Clapper, Patti, Schweizer and Mason

Mesothelioma attorneys believe that the test will be useful to physicians in making pleural mesothelioma diagnoses because the microRNA is better equipped to distinguish between mesothelioma and other similar diseases, including a cancer of the glandular tissue (adenocarcinoma). Physicians rely at present on x-rays, MRI and CT scans and surgical biopsies. Mesosthelioma, which is usually caused by exposure to asbestos, can take years to develop after exposure, mesothelioma attorneys have found. Pleural mesosthelioma, is usually a fatal form of cancer with a low survival rate. Rosetta Genomics will continue to develop their diagnostic testing in the United Sates with the recent acquisition of Parkway Clinical Laboratories in Bensalem, PA.